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Endothelin (ET)-1 can act as an autocrine/paracrine growth factor or an antiapoptotic factor in human cancers. To study the role of
ET-1 in human colon cancer, proliferation and apoptosis of colon carcinoma cells was investigated using human HT-29 and SW480
colon carcinoma cells. ET-1 was secreted by these cells. Treatment of cells with bosentan, a dual ETA/B-receptor antagonist,
decreased cell number. Inhibition of DNA synthesis by bosentan was observed only in the presence of serum. Exogenously added
ET-1 did not increase DNA synthesis in serum-deprived cells. SW480 cells were sensitive and HT-29 cells were resistant to FasL-
induced apoptosis. Bosentan sensitised resistant HT-29 cells to FasL-induced, caspase-mediated apoptosis, but not to TNF-a-induced
apoptosis. Bosentan and/or FasLigand (FasL) did not modulate the expression of caspase-8 or FLIP. Bosentan sensitisation to
apoptosis was reversed by low concentrations (10
 13–10
 10 M), but not by high concentrations (10
 9–10
 7 M) of ET-1. These
results suggest that the binding of ET-1 to high-affinity sites inhibits FasL-induced apoptosis, while the binding of either ET-1 or
receptor antagonists to low-affinity sites promotes FasL-induced apoptosis. In conclusion, endothelin signalling pathways do not
induce human colon cancer cell proliferation, but are survival signals controling resistance to apoptosis.
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Endothelins (ETs) 1, 2 and 3 are a family of 21 amino-acid peptides
that mediate a variety of physiological functions, including cell
growth and death. ETs are produced from inactive intermediates
that are cleaved to yield active peptides by ET-converting enzyme
(ECE), a zinc metalloprotease, specifically responsible for this key
step (Shimada et al, 1995; Yanagisawa et al, 1998). The effects of
ETs on mammalian cells are mediated by two distinct subtypes of
G protein-coupled receptors, ETA and ETB (Arai et al, 1990;
Sakurai et al, 1990), which are expressed in various tissues and
stimulate several intracellular signalling systems. Several human
cancer cell lines produce ET-1, with autocrine/paracrine growth
factor functions (Kusuhara et al, 1990; Shichiri et al, 1991). Plasma
ET-1 levels are elevated in patients with advanced colorectal cancer
and ET-1 may be associated with metastatic progression (Shankar
et al, 1998; Asham et al, 2001). Recently it has been suggested that
ET-1, in addition to its mitogenic effects, may attenuate apoptosis.
This novel role for ET-1 was demonstrated for rat endothelial cells
(Shichiri et al, 1997), human smooth muscle cells (Wu-Wong et al,
1997), rat colon carcinoma cells (Peduto-Eberl et al, 2000) and
human glioblastoma cells (Egidy et al, 2000c).
Proliferation and cell death must be properly balanced in order
to maintain tissue homeostasis. This is achieved in part through
mechanisms that interconnect the signalling pathways regulating
these processes. Apoptosis is an active cell death process that takes
place in a wide spectrum of physiological situations and is induced
by several stimuli, including cytokines of the tumour necrosis
factor (TNF) family. Interaction between the Fas receptor (CD95/
APO-1), a member of the TNF-receptor family, and Fas ligand
(FasL) triggers a pathway to cell death. However, resistance to cell
death induced by the engagement of FasL on its receptor has been
described in many cancers, involving various mechanisms, and
suggesting that antiapoptotic pathways allow transformed cells to
escape death. Susceptibility of a cell to apoptosis is also influenced
by its state of proliferation and differentiation, depending on the
particular cell type.
We have previously shown that the Fas/FasL and ET-1 systems
are expressed in human colon carcinoma and in rat colon
carcinoma cell lines (Peduto-Eberl et al, 1999, 2000b; Egidy et al,
2000a,b). In human glioblastoma cells, blockade of the ET-1
pathway sensitised tumour cells to FasL-mediated apoptosis,
decreasing the level of the short form of the FLICE/caspase-8-
inhibitory protein (FLIP) in these cells (Egidy et al, 2000c). On the
assumption that ET-1 might be also involved in resistance of
human colon carcinoma cells to FasL-induced apoptosis, we
studied the response of human colorectal cancer cell lines to ET-1
and ET-receptor antagonists.
MATERIALS AND METHODS
Immunohistochemistry
Human colon tissues were retrospectively selected from surgical
colectomy specimens performed for cancer treatment. Immuno-
histochemical detection of ET-1 in paraffin-embedded human
colon cancer tissue was performed essentially as previously
Received 16 September 2002; revised 21 November 2002; accepted 25
November 2002
*Correspondence: Dr L Juillerat-Jeanneret;
E-mail: lucienne.juillerat@chuv.hospvd.ch
British Journal of Cancer (2003) 88, 788–795
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sdescribed (Egidy et al, 2000a,b,c) using a monoclonal anti-ET-1
antibody (ABR, Alexis Corporation, La ¨ufelingen, Switzerland).
Detection of mRNAs by RT–PCR
Human colon carcinoma cell lines were from ATCC (American
Tissue Type Collection, Manassas, VA, USA). Cells were grown in
DMEM medium (Gibco-BRL, Basel, Switzerland) containing
4.5gl
 1 glucose, 10% fetal calf serum (FCS) and antibiotics. Total
RNA from confluent cells was prepared using Trizol reagent
(Gibco-BRL) and RT–PCR for the ET-1 system was performed
according to standard procedures and specific primers as follows:
PPET-1 (Egidy et al, 2000a, 341bp; Pagotto et al, 1995, 304bp);
ECE-1 (Egidy et al, 2000a, 622bp); ECE1a,b,c,d (Egidy et al, 2000c,
353, 347, 348, 369bp, respectively); ETA (Egidy et al, 2000a, 675bp,
or (sense) 50TTT GAT GTG GCA TTG AGC ATA CAG30 (reverse)
50CCT TTT GAT CAC AAT GAC TTT30, 299bp); ETB (Egidy et al,
2000a, 400bp, or (sense) 50TTC CAA CGC CAG TCT GGC GCG
GTC30 (reverse) 50GTC AAT ACT CAG AGC ACA TAG ACT30,
425bp); s-,l-FLIP (Egidy et al, 2000c, 507, 391bp, respectively); Fas
((sense) 50CAG AAC TTG GAA GGC CTG CAT C 30 (reverse)
50TCT GTT CTG CTG TGT CTT GGA C 30, 682bp); FasL ((sense)
50CAA CTA TCT CGG TGC CTG TAA C30 (reverse) 50 CAG CTC
TTC CAC CTA CAG AAG30, 558bp). To ensure the quality of
RNAs, amplification reactions were performed with pairs of
primers specific for human glyceraldehyde-phosphate dehydro-
genase (Gapdh) (Egidy et al, 2000a, 456bp).
Measurement of ET secretion
HT-29 and SW480 cells were grown to confluence in DMEM
containing 4.5gl
 1 glucose and 10% FCS, fresh medium with or
without FCS was added and collected after 24, 48 or 72h. The
quantification of ET-1 in cell culture supernatants was performed
using an enzyme-linked immunoassay (Biomedica, Wien, Austria)
according to the supplier’s instructions. Crossreactivity with big-
ET-1, ET-2 and ET-3 was o1, 100 and o5%, respectively,
according to the manufacturer’s specification.
Evaluation of ET-1 binding to cells
Cells were grown to confluence in the presence of FCS. The
medium was changed to a new medium containing 10% FCS and
50pM
125I-ET-1 (Anawa Trading, Wangen, Switzerland), and either
80 or 8mM bosentan or 3nM ET-1 (Bachem, Bubendorf, Switzer-
land). After 1h at room temperature, cells were washed, extracted
in 1% SDS 0.1 N NaOH and supernatants and cell extracts counted
in a g-counter (Cobra, Packard, Perkin-Elmer, Hunenberg,
Switzerland).
Evaluation of cell growth
(3,4,5-Dimethylthiazol-yl)-2,5-diphenyl tetrazolium, (MTT) reduc-
tion was used to quantify metabolically active cells. Briefly,
following treatment, cells were exposed to 0.25mgml
 1 MTT
(Sigma, Buchs, Switzerland) for 2h. The cells were examined under
a microscope to ascertain the density of violet spots corresponding
to active mitochondria in order to exclude a potential mitochon-
drial toxicity of the compounds. The supernatant was then
removed and the precipitated formazan was dissolved in 0.1 N
HCl in isopropanol and quantified at 540nm (iEMS, Labsystems,
Bioconcepts, Allschwil, Switzerland).
Thymidine incorporation was used to assess cell proliferation.
Cells were grown to 75% confluence, FCS was removed for
16–24h, when indicated, and increasing concentrations of ET-1 or
bosentan were added to the cells. At different times following agent
addition, 1mCiml
 1 [
3H]thymidine (Amersham Pharmacia, Du ¨-
bendorf, Switzerland) was added for 3–24h and incorporation was
quantitated in a b-counter (Rackbeta, LKB, Bertholel, Regensdorf,
Switzerland) after precipitation with 10% trichloracetic acid and
solubilisation in 0.1 N NaOH.
FasL-induced cell death
The murine neuroblastoma cell line Neuro-2A FasL has been
transfected to produce soluble murine FasL (Rensing-Ehl et al,
1995) and is used as a source of active FasL as previously described
(Peduto-Eberl et al, 2000). Briefly, the collection of supernatants of
Neuro-2A FasL cells was performed in a medium containing less
than 0.5% FCS and the FasL titre of the preparations was
controlled using murine 497 glioblastoma cells, which are
responsive to FasL. Supernatant from neo vector Neuro-2A cells
were used as control for FasL-containing supernatants. HT-29 and
SW480 cells were maintained in DMEM 4.5gl
 1 glucose supple-
mented with 10% FCS. Cells were grown to half confluence, washed
to eliminate any ET-1 in the culture medium for the initial period
of exposure to effectors and incubated at 371C with ET-receptor
antagonists (bosentan (Actelion, Basel, Switzerland), BQ123 or
BQ788 (both from RBI, Natick, MA, USA) at the indicated
concentrations) in the presence or absence of FasL-containing
supernatant and of 10% FCS for 24 or 48h. For some experiments
performed with bosentan, exogenous ET-1 was added at increasing
concentrations from 10
 13 to 10
 7 M, together with FasL-contain-
ing supernatant for 24h. For experiments performed with the
caspase inhibitor zVAD-fmk (Bachem, Bubendorf, Switzerland),
cells were preincubated with the inhibitor at the indicated
concentrations and time, prior to the addition of bosentan and/
or FasL-containing supernatant and incubation was continued for
24h. As a control for the specificity of the FasL induction of
apoptosis, cells were exposed to FasL-containing conditioned
medium from Neuro 2A cells in the presence of 50mgml
 1 of the
FasL- binding Fas-Fc-IgG fusion protein (Alexis Corporation,
Taufaliugeu, Switzerland) to deplete specifically FasL from
conditioned medium and bosentan. After 24h, apoptosis was
evaluated in adherent cells.
Cell death evaluation
Apoptosis was quantified as previously described (Egidy et al,
2000c; Peduto-Eberl et al, 2000) using the Cell Death Detection
ELISA
PLUS (Roche, Rotkreuz, Switzerland), a photometric enzyme-
linked immunoassay for quantitative in vitro determination of
cytoplasmic histone-associated DNA fragments (mono- and
oligonucleosomes), according to the supplier’s instructions.
Increase in absorbance at 405nm is proportional to apoptosis,
and the enrichment in dead cell proportion (apoptosis index) was
calculated as the ratio of absorbance of treated cells/absorbance of
untreated cells.
Flow cytometric analysis
HT-29 cells were detached by incubation with EDTA (1mgml
 1)a t
371C for 10min, essentially as previously described (Peduto-Eberl
et al, 1999). After washing in PBS containing 2% FCS and
incubation at 41C for 30min with the monoclonal mouse IgG1
anti-human Fas antibody (SM1/17) (Alexis Corporation, Ta ¨ufelin-
gen, Switzerland), the cells were washed again and incubated with
anti-mouse IgG-FITC (fluoroisothiocyanate)-conjugates (Alexis
Corporation, Ta ¨ufelingen, Switzerland). After a further wash, cells
were suspended in PBS containing 2% FCS and analysed on a
FACScan flow cytometer (Becton-Dickinson and Co., San Jose, CA,
USA). To label dead cells, 0.5mgml
 1 propidium iodide was added
to the cells before analysis. Irrelevant monoclonal IgG antibodies
(at equivalent concentrations) were used as isotype controls.
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sDetermination of p42/p44 MAP kinase/extracellular signal
regulated kinase (ERK), FLIP and caspase-8 by Western
blotting
Cells were grown in the presence of FCS, deprived of serum for
24h and exposed or not to ET-1 for 10min. Cell cultures were
extracted using 0.1% Triton X-100 in the presence of a cocktail of
protease inhibitors (Roche, Rotfzreuz, Switzerland) and submitted
to SDS electrophoresis. Following transfer, the membrane was
probed using monoclonal antiphosphorylated p42/p44 antibody
(clone E10) (New England Biolabs, Bioconcepts, Alschwill,
Switzerland) as previously described (Egidy et al, 2000c).
Alternatively, cell extracts were exposed following blotting to
anti-caspase-8 (New England Biolabs), anti-FLIP (a kind gift of J
Tschopp, Lausanne, Switzerland) or anti a-SMA (Sigma, Buchs,
Switzerland) monoclonal antibodies.
Calculations of results
Each experiment was repeated at least three times unless otherwise
stated. Means and s.d. were calculated. Statistical significance was
assessed using an unpaired two-tailed Student’s t-test.
RESULTS
Expression of the ET-1 system in human colon and colon
carcinoma cells
The presence of immunoreactive ET-1 was assessed in human
normal colon (Figure 1A, upper panel) and colon carcinoma
(Figure 1A, lower panel). Cancer cells, but not normal epithelial
cells, ubiquitously expressed ET-1. The expression of the mRNAs
of the components of the ET system in HT-29 and SW480 human
colon carcinoma cells was evaluated using RT–PCR. ETA and ETB
receptors, ECE-1 and PPET-1 mRNAs confirmed the presence of
all the transcripts of the ET system in these cells (Figure 1B).
Confluent cultures of SW480 (4 10
4cellscm
 2) and HT-29
(5 10
4cellscm
 2) cells secreted ET-1, either in the absence or
presence of FCS (Figure 1C). The presence of cell membrane and
functional ET-1 receptors in SW480 and HT-29 cells was evaluated
using
125I-ET-1 binding (Figure 1D) and the phosphorylation of
ERK, a known intracellular mediator of ET-1 (Figure 1E). SW480
cells, but not HT-29 cells, could bind ET-1 at concentrations
corresponding to equilibrium constants of the receptors
(Figure 1D). In SW480 cells exposed to fresh culture medium,
phosphorylated-ERK was detected 10min after addition of ET-1
(Figure 1E, 10min), while both in SW480 cells and HT-29 cells,
after 24h culture without medium change, phosphorylation of ERK
was detected and was not further increased by addition of ET-1
(Figure 1E, 24h).
ET-1 is not a proliferation-inducing factor in human colon
carcinoma cells
In serum-deprived colon carcinoma cells, ET-1 did not induce cell
proliferation as determined either by MTT reduction, labelling
metabolically active cells (Figure 2A) or DNA synthesis, as
determined by thymidine incorporation (Figure 2B). Blockade of
ETA and ETB receptors by bosentan dose-dependently decreased
the amount of metabolically active HT-29 and SW480 cells
(Figure 2C). However, bosentan did not decrease DNA synthesis
(Figure 2D).
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Figure 1 Imunnohistochemical localisation of ET-1 and expression of the mRNAs of the ET-1 pathway in human colon carcinoma cells. (A) ET-1
immunoreactivity is ubiquitously localised in tumour cells of colon carcinoma (lower panel), but not in nontumoral epithelial cells of normal colon (upper
panel). (Original magnification:  200). (B) HT29 and SW480 cells express the mRNAs of the ET system (PPET-1, ECE-1, ETA and ETB). RT–PCR was
performed on total RNA extracted from the colon carcinoma cell lines. Gapdh: glyceraldehyde-phosphate dehydrogenase. Two independent experiments
gave similar results. (C) HT29 and SW480 cells secrete ET-1. HT-29 and SW480 cells were grown for 2 days in a culture medium containing 10% FCS, then
half of the culture wells were deprived of serum and ET-1 was measured at various time intervals in the supernatants. ~: HT-29 cells+FCS, }: HT-29 cells
no FCS; ’: SW480 cells+FCS, &: SW480 cells no FCS. (D) SW480 cells bind
125I-ET-1 (50pM), which is displaced by bosentan (8 or 80mM) or ET-1
(3nM). Cells were grown in the presence of FCS for 3 days, and ET-1 binding was assessed in the presence of FCS (a: control; b: bosentan 80mM; c: bosentan
8mM; d: ET-1 3nM). (E) ET-1 induces ERK phosphorylation in SW480 cells, indicating the presence of functional receptors. Cells were deprived of FCS for
24h, then the medium was changed to a fresh medium without FCS either containing 0.4nM ET-1 [+] or not containing ET-1 [ ], and ERK phosphorylation
was determined by Western blotting after 10min exposure to ET-1. After 24h in the absence of FCS without medium change, ERK is phosphorylated at a
comparable extent in SW480 cells or HT-29 cells, exposed [+] or not exposed [ ] to exogenous ET-1 (0.4nM) for 10min.
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sIn serum-exposed cells, high (80mM), but not low (8mM),
bosentan concentrations decreased DNA synthesis (Figure 3A). In
HT-29 cells (Figure 3B), bosentan time-dependently decreased
DNA synthesis, which was abolished by addition of ET-1
conjointly to bosentan (Figure 3C). These results suggest that
bosentan interfere with serum-derived factors in cells unable to
bind ET-1 at concentrations corresponding to ETA/B-receptor
equilibrium constants.
Bosentan sensitises human colon carcinoma cell
to FasL-induced apoptosis
Increasing concentrations of bosentan were added to half
confluent cells and nucleosomal fragmentation was quantified.
Bosentan alone dose-dependently increased apoptosis in SW480
cells, while it had little effect on HT29 cells (Figure 4, open
symbols). In the presence of FasL, HT29 cells were partially
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Figure 2 Role of bosentan and ET-1 in HT-29 and SW480 serum-deprived cells. Cells were grown to half-confluence, deprived of FCS, then bosentan or
ET-1 were added for 24h. Either MTT assay was performed or [
3H]thymidine was added for the last 3h of incubation to quantitate alive cell number or
DNA synthesis, respectively. (A) ET-1 does not increase the number of metabolically active cells quantified using an MTT assay. (B) ET-1 does not induce
DNA synthesis in HT-29 and SW480 cells. Grey bars: HT-29 cells, black bars: SW480 cells. (C) Bosentan decreases metabolically active cell number
quantified using an MTT assay, HT-29 cells (~), SW480 cells (&). (D) Bosentan does not inhibit DNA synthesis. White bars: no bosentan, grey bars: 10mM
bosentan; black bars: 80mM bosentan. Experiments were repeated three times with identical information.
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Figure 3 Bosentan inhibits plasma-induced DNA synthesis in colon carcinoma cells. HT-29 or SW480 cells were grown with 10% FCS, then exposed
to bosentan in the absence of FCS for 2–9h. [
3H]Thymidine was added for the last 2h of incubation. (A) Following culture in the presence of 10% FCS,
0mM (black bars), 8mM (white bars) or 80mM (grey bars) bosentan was added for 9h. (B) Following 24h culture of HT-29 cells in the presence of either
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sresistant to FasL-mediated apoptosis after 24h of treatment, while
SW480 cells were sensitive to FasL-induced apoptosis (Figure 4,
closed symbols), confirming previous information for SW480 cells
(Mo ¨ller et al, 1994). Treatment of HT-29 cells with FasL and
increasing concentrations of bosentan for 24h significantly
enhanced FasL-mediated apoptosis (Figure 4, closed symbols),
while it had no enhancing effects on the sensitivity of SW480 cells
to FasL. Comparable information was obtained using propidium
iodide-labelled HT-29 cells and FACS analysis, as previously
described for rat colon carcinoma cells (Peduto-Eberl et al, 2000)
(results not shown). The addition of Neuro2A-control medium
alone or in the presence of bosentan did not potentiate apoptosis
and apoptosis was inhibited in cells exposed to FasL in the
presence of the FasL-binding Fas-Fc-IgG fusion protein and
bosentan (results not shown), confirming that apoptosis was
because of Fas–FasL interactions. By RT–PCR, both cell lines
expressed Fas mRNA, but only SW480 cells express FasL mRNA
(not shown).
Two ET-receptor antagonists structurally unrelated to bosentan,
BQ123 (ETA-specific) and BQ788 (ETB-specific), were investigated.
Both BQ123 or BQ788 (at 80mM concentrations) alone or in
combination significantly (Figure 4C; Po0.0004 for all treatments
vs control), but not synergistically, sensitised HT29 cells to FasL-
mediated apoptosis like bosentan. This information suggests that
both ETA and ETB receptors can transmit the antiapoptotic signal.
Other apoptosis-inducing factors, the glucocorticoid dexametha-
sone (10mgml
 1) or TNF-a (100Uml
 1) (Figure 5), did not
potentiate the effects of bosentan on decreasing the number of
metabollically active cells, indicating that bosentan sensitisation to
apoptosis is specific to FasL-induced apoptosis in these cells.
Addition of low concentrations of exogenous ET-1 (10
 13–
10
 10 M) to HT-29 cells together with 80mM bosentan and FasL
antagonised bosentan sensitisation to FasL-induced apoptosis
(Figure 6A), confirming that bosentan enhancement of FasL-
induced apoptosis was dependent on the ET-1 pathway. However,
at higher concentration of ET-1 (10
 9–10
 7 M), the antagonistic
effect of ET-1 was no longer observed, indicating that at high
concentrations ET-1 promoted apoptosis. Similar observation was
obtained using the FasL-resistant, bosentan-sensitive (Peduto-
Eberl et al, 2000) rat colon carcinoma PROb and REGb cells
(Figure 6B).
Evaluation of the caspase-8 pathway in bosentan-mediated
effects in colon carcinoma cells
To study the mechanism of bosentan sensitisation to FasL-
mediated apoptosis, the expression of Fas/FasL, FLIP and the
involvement of caspase activity were evaluated after bosentan and/
or FasL treatment. By flow cytometry, Fas was expressed at low
levels in HT29 cells, and its expression was not increased by
exposure to bosentan (results not shown) suggesting that ET-1
does not interfere with the Fas pathway at the receptor expression
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Figure 4 Bosentan sensitises FasL-resistant HT-29, but not FasL-sensitive SW480 carcinoma cells to FasL-induced apoptosis. (A) Half-confluent HT-29
(~, }) or SW480 (’, &) cells were incubated with increasing concentrations of bosentan (10–270mM) in the absence (open symbols) or in the presence
(closed symbols) of FasL-containing supernatant from neo-Neuro2A/FasL cells. Apoptosis was evaluated after 24h of incubation. (B) Two ET-receptor
antagonists structurally unrelated to bosentan, BQ123 (ETA-specific) and BQ788 (ETB-specific) significantly, but not synergistically, sensitise HT29 cells to
FasL-mediated apoptosis. Half-confluent HT-29 cells were incubated in the presence of 80mM of either BQ123 or BQ788 or BQ123 and BQ788 in
combination, and FasL-containing supernatant from neo-Neuro2A/FasL cells. (Apoptosis index¼1 is defined as the apoptosis measured in the absence of all
effectors). Apoptosis was evaluated after 24h of incubation. Means7s.d. were calculated. One representative experiment out of four is shown.
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slevel, in contrats with IFN-g-dependent induction of Fas in these
cells (Mo ¨ller et al, 1994). Both cell lines expressed mRNAs for the
long and short form of FLIP (Figure 7A) and the long form of FLIP
protein (not shown); however, only SW480 cells expressed
detectable levels of the short form of FLIP protein (Figure 7B).
Exposure of SW480 cells to bosenatn and/or FasL neither
decreased the level of the short form of FLIP as previously shown
for glioblastoma cells (Egidy et al, 2000c) (Figure 7B), nor modify
caspase-8 expression (Figure 7C). The long form of FLIP was not
modified in both cell lines by these treatments (not shown).
Involvement of caspase activity in FasL/bosentan-dependent
apoptosis in HT29 cells was therefore demonstrated: pre- and
coincubation of cells with 100mM of the general caspase inhibitor
zVAD-fmk in the presence of both bosentan and FasL in HT-29
cells inhibited apoptosis (Figure 8).
DISCUSSION
Tumour progression is dependent upon equilibrium between cell
death-promoting and growth-promoting factors. Death-promoting
factors include FasL, while ET-1 is considered as a growth-
promoting factor. We have previously shown that both the
complete ET-1 (Egidy et al, 2000a,b) and Fas/FasL (Peduto-Eberl
et al, 1999) systems are expressed in human normal colon and
colon carcinoma. We demonstrate here that ET-1 immunoreactiv-
ity is highly expressed in human colon cancer and that human
colon carcinoma cells secrete ET-1. Several human cancer cell lines
have been shown to produce ET-1 with autocrine/paracrine growth
factor functions (Kusuhara et al, 1990; Shichiri et al, 1991), and
ET-1 has been implicated in metastasis of colon cancer (Shankar
et al, 1998; Asham et al, 2001) and as an apoptosis survival factor
in endothelial cells (Shichiri et al, 1997), smooth muscle cells (Wu-
Wong et al, 1997) and fibroblasts (Shichiri et al, 1998). Resistance
to FasL-induced apoptosis of rat colon carcinoma cells involved
the ET-1 system and in a syngenic rat model of carcinomatosis,
bosentan treatment resulted in a trend towards a lower tumour
grading (Peduto-Eberl et al, 2000). Thus in the present approach,
we investigated the effects of blockade of the ET-1 system in
human colon cancer cells.
The human colon carcinoma HT-29 and SW480 cells expressed
all the components of the ET-1 and Fas/FasL systems and secreted
ET-1, thus representing good models to study the role of ET-1 in
colon cancer. Exogenously added ET-1 was not directly involved in
the induction of cell proliferation. However, activation of the ET-1
pathway was a necessary permissive signal for colon carcinoma
cell survival. This information is in agreement with our previous
observation that in induced colon carcinomatosis in the rat,
bosentan, a dual ETA/ETB-receptor antagonist (Clozel et al, 1993),
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0
20
40
60
80
100
120
%
 
G
r
o
w
t
h bos
bos+dex
bos+TNF
dex
cont
TNF
Figure 5 TNF-a or dexamethasone do not potentiate bosentan effects
on growth of human colon carcinoma cells. Half-confluent HT-29 or
SW480 cells were incubated with bosentan (bos) and/or TNF-a (TNF) or
dexamethasone (dex). MTT assay was performed for the last 3h of
incubation to quantitate metabolically active cell number. Means7s.d. were
calculated. One representative experiment out of two is shown.
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Figure 6 Low concentrations of exogenous ET-1 antagonises and high concentrations of ET-1 promotes bosentan-induced apoptosis. (A) Low
concentrations of exogenous ET-1 antagonises bosentan-induced apoptosis (apoptosis index¼1 in the absence of bosentan, FasL and ET-1) in HT-29 cells.
Half-confluent human HT-29 colon carcinoma cells were incubated simultaneously with bosentan (80mM), FasL and increasing concentrations of ET-1
(10
 13–10
 10 M). Apoptosis was evaluated after 24h of incubation. (B) High concentrations of ET-1 promotes apoptosis (apoptosis index¼1 in the
presence of bosentan and FasL, without ET-1). Half-confluent human HT-29 (’) or rat PROb (m) and REGb (~) colon carcinoma cells were incubated
simultaneously with bosentan (80mM for HT-29 cells; or 25mM for PROb and REGb cells), FasL and increasing concentrations of ET-1 (10
 13–10
 7 M).
Apoptosis was evaluated after 24h of incubation. Means+s.d. were calculated. One representative experiment out of three is shown.
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shas the potential to reduce initial tumour growth (Peduto-Eberl
et al, 2000; Egidy et al, 2000). In human colon carcinoma cells,
bosentan induced low levels of apoptosis in SW480 cells and
potentiated FasL-mediated apoptosis in FasL-resistant HT-29 cells.
In our experiments, exposure to bosentan did not significantly
modify Fas, FLIP or caspase-8 expression, which suggests that the
ET-1 pathways does not directly interfere with expression of the
molecules of the Fas pathway in the control of apoptosis in these
cells. This information also suggests that antiapoptotic molecules
other than FLIP or different intracellular regulatory pathways are
involved in carcinoma cells when compared to glioblastoma cells,
as we had previously shown (Egidy et al, 2000c) that in human
glioblastoma cells, bosentan could decrease the levels of the short
form of the FLIP protein. However, in human colon cancer as in
glioblastoma cells (Egidy et al, 2000c), ET-1 is not a proliferation-
inducing factor, but is necessary for the survival of cancer cells.
In our experiments, low concentrations of ET-1 (10
 13–10
 10 M)
antagonised bosentan-induced apoptosis in HT-29 cells, even in
the presence of a high concentration (80mM) of bosentan. These
low concentrations of ET-1 are comparable to ET-1 plasma levels
and to the levels secreted by colon carcinoma cells. Thus ET-1 is
not a proliferation-inducing factor for human colon carcinoma
cells; however, ET-1 is necessary for tumour cell survival. At high
ET-1 concentrations, ET-1 did not stimulate DNA synthesis but
sensitised HT-29 death-resistant cells to FasL/bosentan-induced
apoptosis. Thus, at physiological plasma concentrations, ET-1 may
exert an antiapoptotic effect, while at high concentrations ET-1
and bosentan are proapototic. Therefore, ET-1 production by
colon cell lines is sufficient for this peptide to act as an autocrine
survival factor, but not a proapoptotic factor. Interestingly,
exogenous radioactive ET-1, at concentrations corresponding to
the affinity constants of this peptide for its receptors, was bound
only by SW480 cells, not by HT-29 cells. These results suggest that
ET-receptor antagonists have binding sites different from the cell-
surface ETA/B receptors, and also suggest that ET peptides and
antagonists, including bosentan, BQ123 or BQ788, have two
binding sites in human colon cancer cells: a high-affinity binding
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Figure 7 Expression of the FLIP and caspase-8 in HT29 and SW480 cells. (A) HT-29 and SW480 cells express the long and the short FLIP mRNAs. RT–
PCR was performed on total RNA extracted from the two tumoral cell lines. (B) Bosentan and FasL do not modulate the expression of the short form of
FLIP in SW480 cells. Half-confluent SW480 cells were incubated with bosentan and/or FasL for 24h and the presence of sFLIP was determined by Western
blotting. (C) Bosentan and FasL do not modulate the expression of caspase-8 in HT-29 and SW480 cells exposed to bosentan and FasL. Half-confluent
SW480 or HT-29 cells were incubated with bosentan and/or FasL for 24h and the presence of caspase-8 was determined by Western blotting. Two
independent experiments gave similar results.
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Figure 8 Bosentan sensitisation to FasL-induced apoptosis in HT-29 cells
is blocked by the general caspase inhibitor zVAD-fmk. Cells were
preincubated with 100mM zVAD-fmk for 1h, then 150mM bosentan
(without FasL) or 80mM bosentan (with FasL) were added. Incubation was
continued for 24h and apoptosis was evaluated. Values are the mean+s.d.
of two independent determinations. Po0.01: bosentan+FasL vs control;
z-VAD-fmk+bosentan+FasL vs bosentan+FasL.
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ssite, whose occupancy by ET-1 protects against FasL-induced
apoptosis, and a low-affinity binding site, whose occupancy either
by ET-1 or receptor antagonists sensitises cells to apoptosis and
whose exact nature is presently not defined. Alternatively, the
effects of ET-receptors antagonists involve intracellular targets,
and the high concentrations of antagonists necessary to observe an
effect depends on delivery of the molecules into the cells.
Upon interaction of Fas, a member of the TNF family, with its
ligand, FasL, death is induced via caspase activation. Several
mechanisms may render cells resistant to FasL-induced apoptosis.
Bosentan sensitisation to FasL-mediated apoptosis in HT29 cells
was completely blocked by the general caspase inhibitor zVAD-
fmk, demonstrating the involvement of the caspase proteases.
These results suggest that ET-1-receptor blockade allows HT-29
cells to undergo caspase activation, via the Fas pathway. However,
ET-1 does not sensitise cells to death induced by TNF-a, another
member of the TNF-death receptor family.
In conclusion, we have shown that ET-1 is not a proliferation-
inducing factor in human colon carcinoma. Blockade of ET
receptors either induces apoptosis or sensitises cells to Fas-
induced apoptosis. In colon cancer cells, low concentrations
of ET-1, either added exogenously or secreted by the tumour cells,
are permissive for colon cancer cell survival, promoting resistance
to FasL-mediated apoptosis, while high concentrations of either
receptor antagonists or ET-1 promote apoptosis.
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